Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDTXNASDAQ:ENGNNASDAQ:NVCTNASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDTXCidara Therapeutics$17.82-3.0%$21.75$10.00▼$28.42$195.18M0.8968,343 shs168,560 shsENGNenGene$4.50+1.4%$5.81$4.00▼$17.10$229.40M-0.38130,585 shs27,329 shsNVCTNuvectis Pharma$9.05-4.3%$7.72$4.44▼$11.80$211.70M0.23119,014 shs90,205 shsUNCYUnicycive Therapeutics$0.59+7.6%$0.58$0.20▼$1.60$61.24M2.261.43 million shs1.47 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDTXCidara Therapeutics-2.91%-11.81%-20.30%-32.71%-14.16%ENGNenGene+2.54%-4.72%-23.97%-37.11%-73.73%NVCTNuvectis Pharma+1.18%+8.11%+54.07%+75.51%+19.14%UNCYUnicycive Therapeutics+0.46%-11.36%+5.40%-30.78%-60.25%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDTXCidara Therapeutics4.3737 of 5 stars4.63.00.04.62.40.80.0ENGNenGene3.1716 of 5 stars3.55.00.00.01.72.50.6NVCTNuvectis Pharma2.3058 of 5 stars3.50.00.00.01.15.00.6UNCYUnicycive Therapeutics2.5462 of 5 stars3.63.00.00.01.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDTXCidara Therapeutics 3.25Buy$39.14119.66% UpsideENGNenGene 3.00Buy$25.22460.49% UpsideNVCTNuvectis Pharma 3.00Buy$15.6773.11% UpsideUNCYUnicycive Therapeutics 3.25Buy$6.501,001.69% UpsideCurrent Analyst Ratings BreakdownLatest UNCY, CDTX, NVCT, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.004/1/2025UNCYUnicycive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.503/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/12/2025CDTXCidara TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/12/2025CDTXCidara TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$46.003/12/2025CDTXCidara TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/10/2025CDTXCidara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $35.003/7/2025CDTXCidara TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.002/25/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $11.00(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDTXCidara Therapeutics$1.28M153.08N/AN/A($1.82) per share-9.79ENGNenGeneN/AN/AN/AN/A$6.17 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/AUNCYUnicycive Therapeutics$680K90.06N/AN/A($0.11) per share-5.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDTXCidara Therapeutics-$22.93M-$30.09N/AN/AN/A-289.05%-69.64%-33.73%4/28/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%N/ANVCTNuvectis Pharma-$22.26M-$1.11N/AN/AN/AN/A-155.80%-104.02%5/6/2025 (Estimated)UNCYUnicycive Therapeutics-$30.54M-$0.97N/AN/AN/AN/AN/A-29.88%N/ALatest UNCY, CDTX, NVCT, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024UNCYUnicycive Therapeutics-$0.13-$0.26-$0.13-$0.26N/AN/A3/6/2025Q4 2024CDTXCidara Therapeutics-$5.28-$5.38-$0.10-$5.37N/AN/A3/4/2025Q4 2024NVCTNuvectis Pharma-$0.28-$0.36-$0.08-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDTXCidara TherapeuticsN/AN/AN/AN/AN/AENGNenGene$1.5835.13%N/AN/A N/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDTXCidara TherapeuticsN/A3.543.54ENGNenGene0.0816.8716.87NVCTNuvectis PharmaN/A2.742.74UNCYUnicycive TherapeuticsN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDTXCidara Therapeutics35.82%ENGNenGene64.16%NVCTNuvectis Pharma96.77%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipCDTXCidara Therapeutics7.64%ENGNenGene13.70%NVCTNuvectis Pharma35.78%UNCYUnicycive Therapeutics24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDTXCidara Therapeutics9010.95 million6.51 millionNo DataENGNenGene3150.98 million38.16 millionN/ANVCTNuvectis Pharma823.39 million12.41 millionNot OptionableUNCYUnicycive Therapeutics9103.80 million78.78 millionNot OptionableUNCY, CDTX, NVCT, and ENGN HeadlinesRecent News About These CompaniesUnicycive Therapeutics (NASDAQ:UNCY) Price Target Raised to $7.50 at HC WainwrightApril 3 at 4:01 AM | americanbankingnews.comUnicycive Therapeutics price target raised to $7.50 from $4 at H.C. WainwrightApril 2 at 9:07 PM | markets.businessinsider.comNoble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY)April 2 at 9:07 PM | markets.businessinsider.comHC Wainwright Increases Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $7.50April 2 at 8:09 AM | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPSApril 1 at 8:19 AM | marketbeat.comUnicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1 at 7:00 AM | globenewswire.comUnicycive Therapeutics reports FY24 EPS (56c), consensus (51c)April 1 at 12:21 AM | markets.businessinsider.comUnicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business UpdateMarch 31 at 7:00 AM | globenewswire.comUnicycive Therapeutics (UNCY) to Release Earnings on ThursdayMarch 25, 2025 | americanbankingnews.comUnicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on ThursdayMarch 20, 2025 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest UpdateMarch 15, 2025 | marketbeat.comUnicycive to present patient reported outcomes data from UNI-OLC-201 studyMarch 13, 2025 | markets.businessinsider.comUnicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of HyperphosphatemiaMarch 13, 2025 | globenewswire.comUnicycive Therapeutics (NASDAQ:UNCY) Trading Down 2% - Should You Sell?March 8, 2025 | marketbeat.comUnicycive Therapeutics’ OLC shows synergy with tenapanor in published studyFebruary 21, 2025 | markets.businessinsider.comUnicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360February 20, 2025 | globenewswire.comBuy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill BurdenJanuary 29, 2025 | markets.businessinsider.comUnicycive highlights challenges in phosphate managementJanuary 28, 2025 | msn.comUnicycive announces publication of patient perspectives on phosphate managementJanuary 28, 2025 | markets.businessinsider.comHere's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn SituationJanuary 28, 2025 | finance.yahoo.comUnicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney DiseaseJanuary 28, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUNCY, CDTX, NVCT, and ENGN Company DescriptionsCidara Therapeutics NASDAQ:CDTX$17.82 -0.55 (-2.99%) Closing price 04:00 PM EasternExtended Trading$17.80 -0.02 (-0.08%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.enGene NASDAQ:ENGN$4.50 +0.06 (+1.35%) Closing price 04:00 PM EasternExtended Trading$4.47 -0.03 (-0.56%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Nuvectis Pharma NASDAQ:NVCT$9.05 -0.41 (-4.33%) Closing price 04:00 PM EasternExtended Trading$8.82 -0.24 (-2.60%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Unicycive Therapeutics NASDAQ:UNCY$0.59 +0.04 (+7.57%) Closing price 04:00 PM EasternExtended Trading$0.58 -0.01 (-2.03%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
